Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.85 |
| ▸ | BRD4 | O60885 | 1/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.85 |
| ▸ | POLB | P06746 | 1/20 | 0.85 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.85 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | CCR2 | P41597 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5705098 | 0.92 | KDM4E (1.00) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL16801591 | 0.89 | KDM4E (0.75) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL5202689 | 0.85 | HSD11B1 (0.67) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL14181451 | 0.83 | KDM4E (0.63) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL5705116 | 0.82 | KDM4E (0.78) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL27559063 | 0.82 | KDM4E (0.78) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL16801496 | 0.82 | KDM4E (0.76) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL27201572 | 0.82 | HSD11B1 (0.64) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL18324984 | 0.81 | KDM4E (0.76) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL5205141 | 0.81 | HSD11B1 (0.63) | KDM4EBRD4ALDH1A1POLBCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
| WO-2015082499-A2 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD (GB) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367564-A1 | Pharmaceutical Compound | TDO2, IDO1, IDO2 | KDM4E 465/4885BRD4 1542/4885ALDH1A1 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.